| Concord Drugs Ltd | Industry : (Pharmaceuticals) | |
|---|---|---|
|
BSE Code : 538965 |
NSE Symbol : - |
P/E(TTM) : 44.13 |
|
ISIN Demat : INE858L01010 |
Div & Yield% : 0.00 |
EPS(TTM) : 1.55 |
|
Book Value(₹) : 35.43 |
Market Cap(₹Cr) : 90.12 |
Face Value(₹) : 10.00 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|---|
| Gross Sales | 20.89 | 35.55 | 16.84 | 10.07 | 13.38 | 7.96 |
| Excise Duty | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Sales | 20.89 | 35.55 | 16.84 | 10.07 | 13.38 | 7.96 |
| Other Operating Income | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Income | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 |
| Total Income | 20.90 | 35.56 | 16.86 | 10.08 | 13.38 | 7.97 |
| Total Expenditure | 18.66 | 34.13 | 15.97 | 9.07 | 12.45 | 7.04 |
| PBIDT | 2.24 | 1.43 | 0.89 | 1.00 | 0.94 | 0.93 |
| Interest | 0.35 | 0.34 | 0.30 | 0.40 | 0.42 | 0.53 |
| PBDT | 1.89 | 1.09 | 0.60 | 0.61 | 0.52 | 0.40 |
| Depreciation | 0.35 | 0.35 | 0.30 | 0.34 | 0.37 | 0.37 |
| Tax | 0.44 | 0.21 | 0.07 | 0.08 | 0.05 | -0.01 |
| Fringe Benefit Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax | -0.01 | 0.00 | 0.01 | 0.00 | -0.01 | 0.02 |
| Reported Profit After Tax | 1.11 | 0.52 | 0.22 | 0.19 | 0.11 | 0.01 |
| Extra-ordinary Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Adjusted Profit After Extra-ordinary item | 1.11 | 0.52 | 0.22 | 0.19 | 0.11 | 0.01 |
| EPS (Unit Curr.) | 0.84 | 0.46 | 0.16 | 0.19 | 0.11 | 0.01 |
| EPS (Adj) (Unit Curr.) | 0.84 | 0.46 | 0.16 | 0.19 | 0.11 | 0.01 |
| Calculated EPS (Unit Curr.) | 0.84 | 0.39 | 0.16 | 0.19 | 0.11 | 0.01 |
| Calculated EPS (Adj) (Unit Curr.) | 0.84 | 0.39 | 0.16 | 0.19 | 0.11 | 0.01 |
| Calculated EPS (Ann.) (Unit Curr.) | 3.38 | 1.57 | 0.65 | 0.78 | 0.45 | 0.03 |
| Calculated EPS (Adj) (Ann.) (Unit Curr.) | 3.38 | 1.57 | 0.65 | 0.78 | 0.45 | 0.03 |
| Book Value (Unit Curr.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity | 13.18 | 13.18 | 13.18 | 10.00 | 10.00 | 10.00 |
| Reserve & Surplus | 36.45 | 35.34 | 34.82 | 24.42 | 24.23 | 24.11 |
| Face Value | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Public Shareholding (No. Of Shares) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Public Shareholding (% in Equity) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Pledged/Encumbered - No. of Shares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Pledged/Encumbered - % in Total Promoters Holding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Pledged/Encumbered - % in Total Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Non Encumbered - No. of Shares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Non Encumbered - % in Total Promoters Holding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Non Encumbered - % in Total Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PBIDTM(%) | 10.72 | 4.02 | 5.29 | 9.93 | 7.03 | 11.68 |
| PBDTM(%) | 9.05 | 3.07 | 3.56 | 6.06 | 3.89 | 5.03 |
| PATM(%) | 5.31 | 1.46 | 1.31 | 1.89 | 0.82 | 0.13 |
